Guardant Health up as cancer detection test gets FDA's 'breakthrough' tag

ReutersJun 3, 2025 2:48 PM

View all comments（0）



Shares of medical diagnostics firm Guardant Health GH.O up 7.5% at $45.25

GH says the U.S. FDA has granted "breakthrough" tag for its device to detect multiple types of cancer

The multi-cancer detection (MCD) test uses a blood sample to screen for different cancer types in patients aged 45 or older

FDA's breakthrough devices program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review, according to its website

Including session's move, stock up 46.8% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

TradingKey - March 2026 CPI numbers came in very strong, delivering a hefty inflation blow in the aftermath of the US-Iran conflict. The headline measure shot up to +3.3% year-over-year – the best since May 2024 – on an energy shock that pushed gasoline prices up 18.9% YoY. Month-over-month, headlin

Kospi Plunges Over 5% After Nearing 8,000 Points as South Korean Top Official Proposes ‘AI Profit Redistribution’

Tradingkey - During the early trading session on May 12, the KOSPI Index briefly touched the 8,000-point mark at the open before plunging more than 5% to a low of 7,421.71 points. As of press time, the index remains down 1.24% at 7,725.33 points. Samsung Electronics and SK Hynix, which together account for nearly half of the KOSPI's total market capitalization, were the primary drivers of this flash crash. Currently, SK Hynix is down 3.62% at 1.144 million KRW, while Samsung Electronics has fallen 2.28% to 279,000 KRW.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

TradingKey - The U.S. Bureau of Labor Statistics will release the April CPI report on May 12 at 8:30 a.m. ET. Since the outbreak of the U.S.-Iran conflict in late February, the global energy market has experienced the most severe geopolitical supply shock in history. As the conflict enters its third month, traffic through the Strait of Hormuz remains significantly below pre-war levels, with approximately 20% of the world's oil transit routes still facing "interruption." This inflation report will serve as a critical validation window for the transmission effects of oil prices.

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

TradingKey — As the Nasdaq continues to hit consecutive record highs, Michael Burry—who rose to fame during the 2008 subprime mortgage crisis and was the inspiration for the film *The Big Short*—is betting with unprecedented intensity on the bursting of the AI bubble.

Featured Tools